论文部分内容阅读
研究表皮生长因子受体（EGFR）和转化生长因子α（TGF－α）与卵巢癌发生发展的关系．方法：用免疫组化ABC方法检测了EGFR，TGF－α，表皮生长因子（EGF）在72例卵巢肿瘤及正常卵巢组织中的表达情况．结果：TGF－α在卵巢癌中的检出率为71．05％，在良性肿瘤、交界性肿瘤和正常卵巢组织中的检出率分别为3．00％，58．33％％及41．67％，各组与卵巢癌组间均有显著差异（PM0．05）．EGFR在上述4组中的检出率分别为76．32％，40．00％，66．67％和41．67％，除交界性肿瘤组外，其余各组与卵巢癌组相比差异显著（P＜0．05）．在不同临床分期的卵巢癌中，TGF－α和EGFR的检出率分别为Ⅰ期：50％和50％，Ⅱa，b期：70．59％和76．47％，Ⅱc－Ⅳ期：84．62％和92．31％，可以看出TGF－α和EGFR在临床分期越晚的卵巢癌中，其检出率越高，且多数组间存在显著差异（P＜0．05）．EGF在上述各类组织中极少表达．结论：TGF－α和EGFR在卵巢肿瘤中有高水平的表达，且恶性程度越高，表达率越高，提示TGF－α／EGFR自分泌系统在卵巢癌的发生发展中起着重要的作用，而EGF／EGFR这一系统可能在卵巢癌中不发挥作用．
To study the relationship between epidermal growth factor receptor (EGFR) and transforming growth factor-α (TGF-α) and the development of ovarian cancer. Methods: The expressions of EGFR, TGF-α and epidermal growth factor (EGF) in 72 ovarian tumors and normal ovarian tissues were detected by immunohistochemical ABC method. Results: The positive rate of TGF-α in ovarian cancer was 71.05%. The positive rates of TGF-α in benign tumors, borderline tumors and normal ovarian tissues were 3.00%, 58.33%, and 41 respectively. 67%, there was a significant difference between each group and ovarian cancer (PM0.05). The detection rates of EGFR in the above four groups were 76.32%, 40.00%, 66.67% and 41.67% respectively, except for the borderline tumor group, the other groups were significantly different from the ovarian cancer group (P <0.05). In different clinical stages of ovarian cancer, the detection rates of TGF-α and EGFR were stage Ⅰ: 50% and 50%, stage Ⅱ a and b: 70.59% and 76.47%, stage Ⅱc-Ⅳ: 84 .62% and 92.31% respectively. The higher the detection rate of TGF-α and EGFR in ovarian cancer, the later the clinical stage was, there was a significant difference between the two groups (P <0.05). EGF is rarely expressed in all kinds of tissues mentioned above. Conclusion: TGF-α and EGFR are highly expressed in ovarian tumors. The higher the malignant degree, the higher the expression rate of TGF-α / EGFR. The results suggest that the TGF-α / EGFR autocrine system plays an important role in the development of ovarian cancer. The EGF / EGFR system may not play a role in ovarian cancer.